Clinical Trial Update: Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing thalidomide with bortezomib in melphalan-refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Thalomid (thalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: Nordic Myeloma Study Group | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED